Microcap Aridis recruits Takeda vet Paul Mendelman to steer late-stage antibody programs in infectious diseases
A month ago one of Aridis Pharma’s anti-infective antibodies flunked a Phase II test in ventilator-associated pneumonia, forcing the team to abandon the program but leaving chief medical officer Wolfgang Dummer in charge of combing through the data for any insight. But now that responsibility will fall on Paul Mendelman, who’s stepping into the role on an interim capacity as Dummer leaves for personal reasons.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
